Phase 2Active, not recruiting
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease
- Sponsor
- Washington University School of Medicine (Academic or other)
- Enrolment
- 48 planned
- Conditions
- Alzheimer Disease, Early Onset; Mild Cognitive Impairment
- Interventions
- Dasatinib + Quercetin; Placebo Capsules
- Ages
- adults, older adults
- Registry
- NCT04685590
From the registry
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
Primary outcomes
- Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group